Articles and Whitepapers

Commercial Strategy & Planning

The Value of Focus: Portfolio Strategy for BioPharma in a New Era
7/12/2017
Neel Patel, Nelson Azoulay and Adam Mathias
This paper takes a closer look at current trends and their strategic implications for companies seeking to maximize their pipelines, revenues and growth over the next 10-15 years.
Read article

2017 Dealmakers' Intentions Study
6/20/2017
Neel Patel, Sachin Purwar, Adam Mathias and Nelson Azoulay
Now in its ninth year, the inVentiv Health Consulting Dealmakers' Intentions Study is the only forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries. While there are many quality sources of information that look historically at past deal trends, this survey offers a prospective view of the partnering and licensing landscape for the year ahead.
Read article

Know Your Rare Disease Market
5/12/2017
Naveen Murthy, Rafal Kokolus, Rohit Sood
In recent years, rare disease products have become an attractive area for pharmaceutical and biotech development. This article will explore the unique aspects of the rare disease market and how these will drive the commercialization process.
Read article

Companion Diagnostics: The Expanding Reach of Personalized Medicine - In Vivo
3/1/2017
Jessica Lee, Ravi Patel, David Ruch and Katya Magonova
This article, published in the March 2017 issue of In Vivo, discusses the various upsides and unique development and commercialization challenges associated with pairing a therapy with a companion diagnostic.
Read article

Adapt or Fail: Succeeding in the Age of the Organized Customer
9/21/2016
Howard Brock, Tony Lanzone, Tom Principe and Michael Iacoviello
This article takes a look at challenges many pharmaceutical companies continue to face in their approach to the organized customer, and strategies companies should consider for maximizing the many new opportunities that exist for fostering deeper and more mutually valuable customer relationships.
Read article

2016 Dealmakers' Intentions Study
6/9/2016
Neel Patel, Nelson Azoulay and David Ruch
Now in its eighth year, the inVentiv Health Consulting (formerly Campbell Alliance) Dealmakers' Intentions Study is the only forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries. While there are many quality sources of information that look historically at past deal trends, this survey offers a prospective view of the partnering and licensing landscape for the year ahead.
Read article

End-of-Life Care: How to Determine the Right Strategy for Mature Brands
7/6/2015
Tim Arendt and Seb Morisot
With a wide range of generic defense strategies and tactics available, it can be challenging to decide which tactics make the most sense for a given brand. This article from the June 2015 issue of Med Ad News outlines potential strategies for generic defense and the steps necessary to determine the right path forward.
Read article

Dealmakers’ Intentions 2015
6/17/2015
Neel Patel, Jeff Stewart, and Carlos Loya
Following the best year in history for life sciences dealmaking, the seventh annual Dealmakers’ Intentions 2015 examines what the immediate future holds by surveying dealmakers throughout the industry on their intentions for the rest of the year. Providing a unique perspective on the future of licensing and acquisitions, Campbell Alliance’s Dealmakers’ Intentions study of licensing decision makers captures expectations for deal activity, supply and demand for assets at different stages of development, and approaches to valuation.
Read article

The Journey Toward Launch Excellence: Harnessing the Power of Experience and Insights
4/21/2015
Nida Khan, Rohit Sood, and Timo Schwemer
This article examines the importance of the journey toward launch excellence and shows why many companies today are investing in developing the right launch processes and capabilities. The article also examines why knowledge transfer is critical in ensuring the success of a launch, given external pressures, and it details the considerations necessary for developing a robust and continuously evolving launch excellence capability.
Read article

Dealmakers' Intentions 2014
6/23/2014
Neel Patel, Vaibhav Bhatnagar, and Jeff Stewart
The results of the 2014 Dealmakers’ Intentions Study suggest a narrowing of the discount rate, coupled with a strong IPO market, contributing to tempered optimism for M&A/licensing deal activity looking forward into the second half of 2014. The market for dealmaking appears to be softening, and, as such, both buyers and sellers are likely going to need to modify their approach given the potential headwinds.
Read article

Dealmakers’ Intentions 2013
4/24/2013
Jeff Stewart, Neel Patel, David Cao, and Rich Rieger
Now in its fifth year, Dealmakers’ Intentions is Campbell Alliance’s annual survey of licensing decision makers. It is designed to be forward looking, capturing expectations for deal activity, supply and demand for assets at different stages of development, and approaches to valuation. This whitepaper reviews results of Dealmakers’ Intentions 2013 and presents conclusions that are crucial for C-suite executives, as well as executives responsible for dealmaking strategy and the business development function.
Read article

Oncology Index: Maximizing Value in a Changing Paradigm
3/26/2013
During the course of the next decade, the oncology market will continue to evolve. To examine the changes that will likely take place over the next 10 years, Campbell Alliance’s second-annual Oncology Index study is focused on the theme of maximizing value in oncology. Specifically, the study l addresses the implications for the pharmaceutical industry from the standpoint of identifying value, developing value, and delivering value.
Read article

Dow Jones - Biotech Deal Markets Look Favorable For Sellers
6/21/2012
Gregory Millman, Dow Jones
This Dow Jones story reflects on the battle looming between in- and out-licensors around phase III assets according to results of the 2012 Dealmakers' Intentions Survey
Read article

Pharmaceutical Executive - 2012 Dealmakers Outlook
6/1/2012
William Looney, Pharmaceutical Executive
Pharmaceutical Executive convened its annual panel of industry CEOs, presidents, and business development executives to discuss best practices in licensing and M&A for the year ahead. The discussion built on the latest findings from co-host Campbell Alliance’s 2012 Dealmakers’ Intentions Survey.
Read article

2012 Dealmakers' Intentions Survey
6/1/2012
Jeff Stewart
Now in its fourth year, the Campbell Alliance Dealmakers’ Intentions Survey is the only forward-looking measure of deal-making activity in the pharmaceutical and biotech industries. This white paper provides a summary of the 2012 results.
Read article

2011 Dealmakers' Intentions Survey
6/29/2011
Ben Bonifant, Jeff Stewart
The 2011 Dealmakers' Intentions Survey is the only forward-looking measure of deal-making activity in the pharma and biotech industries. Download a summary of the results.
Read article


inVentiv Health Consulting offers world class healthcare consulting services.

Media Contact:

Stephanie Koenig
stephanie.koenig@inventivhealth.com